Assessment of comorbid pathology in patients with breast cancer
- Authors: Orlova D.A.1, Stolyarova V.V.1, Skopina Y.A.1, Shokina S.V.1, Davydova E.A.1
-
Affiliations:
- National Research Ogarev Mordovia State University
- Issue: Vol 34, No 11 (2023)
- Pages: 59-62
- Section: From Practice
- URL: https://journals.rcsi.science/0236-3054/article/view/249514
- DOI: https://doi.org/10.29296/25877305-2023-11-15
- ID: 249514
Cite item
Abstract
The incidence of cardiovascular diseases associated with the treatment of malignancies varies widely depending on the antitumor therapy, its duration, and concomitant diseases of a patient.
Objective. To assess comorbid pathology in patients with breast cancer (BC).
Material and methods. The study included 100 women with breast cancer aged 30 to 80 years. The patients were divided into 5 groups according to their age. The following were assessed: primary and concomitant diseases, history of the primary disease, results of instrumental methods of investigation – ECG, chemotherapy, radiotherapy, and metabolic therapy. The Charlson comorbidity index was calculated, and the one-year death risk and 10-year survival rate in patients with BC were assessed.
Results. The following comorbid pathologies were the most common in the study group patients: hypertension, angina pectoris, chronic gastritis, and myocardiodystrophy. Increasing prevalence of comorbid pathology, significant growth of Charlson comorbidity index score, and deterioration of prognostic indexes were revealed in patients older than 40.
Conclusion. In patients with BC aged 40 and older, cardiovascular pathology, particularly hypertension, angina pectoris, myocardiodystrophy, prevails in the comorbidity structure. Patients most often had a combination of cancer with two or more comorbidities. A significant increase in the Charlson comorbidity index score was observed with age in all patients with BC. According to the prognostic value of the Charlson comorbidity index, 56% of the studied patients with BC have a high risk of one-year mortality and a low 10-year survival rate.
Full Text
##article.viewOnOriginalSite##About the authors
D. A. Orlova
National Research Ogarev Mordovia State University
Email: karpova-dasha1996@mail.ru
ORCID iD: 0000-0001-6398-9993
Russian Federation, Saransk
V. V. Stolyarova
National Research Ogarev Mordovia State University
Email: karpova-dasha1996@mail.ru
ORCID iD: 0000-0002-6164-4737
Professor, MD
Russian Federation, SaranskYu. A. Skopina
National Research Ogarev Mordovia State University
Email: karpova-dasha1996@mail.ru
ORCID iD: 0000-0001-7598-5690
Candidate of Medical Sciences
Russian Federation, SaranskS. V. Shokina
National Research Ogarev Mordovia State University
Author for correspondence.
Email: karpova-dasha1996@mail.ru
ORCID iD: 0000-0001-8650-1778
Candidate of Medical Sciences
Russian Federation, SaranskE. A. Davydova
National Research Ogarev Mordovia State University
Email: karpova-dasha1996@mail.ru
ORCID iD: 0009-0004-4997-8445
Russian Federation, Saransk
References
- Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2017 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2022; 239 с. [Kaprin A.D., Starinskii V.V., Shakhzadova A.O. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2017 godu. M.: MNIOI im. P.A. Gertsena – filial FGBU «NMIRTs» Minzdrava Rossii, 2022; 239 р. (in Russ.)].
- Аксель Е.М. Злокачественные новообразования молочной железы: состояние онкологической помощи, заболеваемость и смертность. Маммология. 2006; 1: 9–13 [Aksel E.M. Breast malignancies: the state-of-the-art of oncological care, morbidity, and mortality. Mammologiya. 2006; 1: 9–13 (in Russ.)].
- Miller K.D., Siegel R.L., Lin C.C. et al. Cancer treatment and survivorship statistics. CA: Cancer J Clin. 2016; 66 (4): 271–9. doi: 10.4236/oju.2013.33031
- Reulen R.C., Winter D.L., Frobisher C. et al. British Childhood Cancer Survivor Study Steering Group. Long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010; 304 (2): 172–9. doi: 10.1001/jama.2010.923
- DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics. CA: Cancer J Clin. 2014; 64 (4): 252–71. doi: 10.3322/caac.21235
- Siegel R., DeSantis C., Virgo K. et al. Cancer treatment and survivorship statistics. CA: Cancer J Clin. 2012; 62 (4): 220–41. doi: 10.3322/caac.21149
- DeSantis C., Ma J., Bryan L. et al. Breast cancer statistics. CA: Cancer J Clin. 2014; 64 (1): 52–62. doi: 10.3322/caac.21203
- Curigliano G., Cardinale D., Suter T. et al. ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy. ESMO Clinical Practice Guidelines. Ann Oncol. 2012; 23 (7): 155–66. doi: 10.1093/annonc/mds293
- Curigliano G., Cardinale D., Dent S. et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA: Cancer J Clin. 2016; 66 (4): 309–25. doi: 10.3322/caac.21341
- Colby S.L., Ortman J.M. Projections of the size and composition of the US population: 2014 to 2060: Population estimates and projections. US Sensus Bureau. Washington, DC: US Department of Commerce, Economics and Statistics Administration, 2017; рр. 25–1143.
- Cubbon R.M., Lyon A.R. Cardio-oncology: Concepts and practice. Indian Heart J. 2016; 68 (1): 77–85. doi: 10.1016/j.ihj.2016.01.022
- Benjamin E.J., Blaha M.J., Chiuve S.E. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics – 2017 Update: A Report From the American Heart Association. Circulation. 2017; 135 (10): 146–603. doi: 10.1161/CIR.0000000000000485
- Gernaat S.M., Ho P.J., Rijnberg N. Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat. 2017; 164 (3): 537–55. doi: 10.1007/s10549–017–4282–9
- Bradshaw P.T., Stevens J., Khankari N. et al. Cardiovascular Disease Mortality Among Breast Cancer Survivors. Epidemiology (Cambridge, Mass). 2016; 27 (1): 6–13. doi: 10.1097/EDE.0000000000000394
- Fowler H., Belot A., Ellis L. et al. Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers. BMC Cancer. 2020; 20 (1): 2. doi: 10.1186/s12885-019-6472-9